Following the announcement of 8th December 2022, the Board of Oximio confirms the appointment of Mykola Nikolaiev as the new Chief Executive Officer (CEO).
Accordingly, Krisztina Varga has resigned from the Board as CEO and Mykola Nikolaiev takes over the role as Oximio embarks on its next development phase.
Mrs. Varga has implemented great changes during her time as our CEO. Under her leadership she has brought international management standards with a multicultural and diverse mindset to the Company, she has overseen the creation of its brilliant new brand, Oximio and she has put our people at the centre of our growth. We thank Krisztina for her leadership, passion and professionalism over the last 3 years and wish her every success in her new ventures.
Mr. Nikolaiev has an established track record of achieving exceptional business results through a high level of commitment, professional growth, and integrity. He has extensive industry experience and an impressive range of academic qualifications. Most recently, as our Chief Business Officer, he has been pivotal in defining our continuity and transformation strategies in response to the unprecedented change taking place in the clinical trials space.
Alexander Skorobogatko, Chairman of the Shareholders said:
“I am delighted to confirm Mykola’s appointment as our new CEO. He is a truly worthy successor. His achievements in senior management and leadership roles within Oximio over the last seven years are testament to his expertise and skills in navigating complex environments. This, coupled with his ability to create valuable partnerships and guide businesses through major periods of change, means he is well placed to build on the strong foundations already laid.”
Mykola Nikolaiev said:
“I am delighted to accept the Board’s proposal to lead Oximio. In a rapidly changing environment, we must keep the confidence of our customers, employees, and shareholders. Oximio has so many strengths, from our customer focus to the use of smart resources, deep local expertise, commitment to quality, proactive business development, and our big belief in care.
Because of these strengths, we continue to achieve excellent results. I rely on you all as the heart of this company because at Oximio, we are and will always be people who care for people.”
For further information, please contact Communications at firstname.lastname@example.org